Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Michela Piezzo, Paolo Chiodini, Maria Riemma, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 17, pp. 6400-6400
Open Access | Times Cited: 85

Showing 26-50 of 85 citing articles:

Discovery of a multi-target compound for estrogen receptor-positive (ER+) breast cancer: Involvement of aromatase and ERs
Cristina Ferreira Almeida, Natércia Teixeira, Ana Oliveira, et al.
Biochimie (2020) Vol. 181, pp. 65-76
Closed Access | Times Cited: 22
Targeted Therapy in HR+ HER2− Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options
Constanze Elfgen, Vesna Bjelic‐Radisic
Cancers (2021) Vol. 13, Iss. 23, pp. 5994-5994
Open Access | Times Cited: 18
Prognostic Significance of Low HER2 Expression in Patients With Metastatic Hormone Receptor-positive Breast Cancer Treated With First Line CDK4/6 Inhibitors: A Greek Multicenter Real-world Data Analysis
George Douganiotis, George Kesisis, Efthalia Lalla, et al.
Cancer Diagnosis & Prognosis (2022) Vol. 2, Iss. 5, pp. 585-591
Open Access | Times Cited: 14
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology
Filippo Merloni, Michela Palleschi, Caterina Gianni, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 7
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure
Filippo Merloni, Michela Palleschi, Chiara Casadei, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 7
A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results
Mauro Cozzolino, Stefania Cocco, Michela Piezzo, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 1, pp. 136-136
Open Access | Times Cited: 16
Eye metastasis in breast cancer: case report and review of literature
Ereny Samwel Poles Saad, HebatAllah Mahmoud Bakri, A Ryan, et al.
ecancermedicalscience (2022) Vol. 16
Open Access | Times Cited: 12
Advanced Breast Cancer Guidelines in Latin America: Assessment, Adaptation, and Implementation of Fifth Advanced Breast Cancer Consensus Guidelines
Fernando Valencia, Henry L. Gómez, Silvia P. Neciosup, et al.
JCO Global Oncology (2024), Iss. 10
Open Access | Times Cited: 2
Real-World Data Analysis of CDK4/6 Inhibitor Therapy—A Patient-Centric Single Center Study
Isabell Ge, Kai Berner, Marlene Mathis, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1760-1760
Open Access | Times Cited: 2
Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2− Metastatic Breast Cancer
RK Goyal, Sean D. Candrilli, Susan Abughosh, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2168-2168
Open Access | Times Cited: 2
CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis
Cailu Luo, Kunlin Yu, Xiaodan Luo, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Real-World Data with CDK4/6 Inhibitors—A Single Center Experience from Croatia
Iva Skočilić, Marin Golčić, Ana Marija Bukovica, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 9, pp. 895-895
Open Access | Times Cited: 2
Binding Modalities and Phase-Specific Regulation of Cyclin/Cyclin-Dependent Kinase Complexes in the Cell Cycle
Michael T. Bergman, Wengang Zhang, Yonglan Liu, et al.
The Journal of Physical Chemistry B (2024)
Closed Access | Times Cited: 2
Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer
Andreas Bjerrum, A.F. Henriksen, Ann Knoop, et al.
BJC Reports (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 2
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): mechanisms of resistance and where to find them
Lorenzo Foffano, Linda Cucciniello, Eleonora Nicolò, et al.
The Breast (2024) Vol. 79, pp. 103863-103863
Open Access | Times Cited: 2
Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysis
Onur Baş, Enes Erul, Deniz Can Güven, et al.
Supportive Care in Cancer (2022) Vol. 30, Iss. 11, pp. 9071-9078
Closed Access | Times Cited: 9
Sacituzumab govitecan in HR+ and HER2- metastatic breast cancer: for all or for some?
Sibylle Loibl, Johannes Holtschmidt
The Lancet (2023) Vol. 402, Iss. 10411, pp. 1394-1395
Closed Access | Times Cited: 5
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells
Nicoletta Cordani, Luca Mologni, Rocco Piazza, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16294-16294
Open Access | Times Cited: 5
Aromatase inhibitors: the journey from the state of the art to clinical open questions
Daniele Generali, Rossana Berardi, Michele Caruso, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Regulation of aromatase expression: Potential therapeutic insight into breast cancer treatment
Deborah Molehin, Stéphanie Filleur, Kevin Pruitt
Molecular and Cellular Endocrinology (2021) Vol. 531, pp. 111321-111321
Open Access | Times Cited: 11
Systemic treatment for hormone receptor-positive/HER2-negative advanced/metastatic breast cancer: A review of European real-world evidence studies
Cláudia Vieira, Maria N. Piperis, Alexandros Sagkriotis, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 180, pp. 103866-103866
Closed Access | Times Cited: 8
Practical Guidance on Abemaciclib in Combination with Adjuvant Endocrine Therapy for Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative High-Risk Early Breast Cancer
Kaitlyn O'Keefe, Neelam V. Desai, Antoinette R. Tan
Breast Cancer Targets and Therapy (2024) Vol. Volume 16, pp. 517-527
Open Access | Times Cited: 1
Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors
Pınar Kubilay Tolunay, Bediz Kurt İnci, Selami Usta, et al.
Current Oncology (2024) Vol. 31, Iss. 12, pp. 7426-7436
Open Access | Times Cited: 1
Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer
Brenno Pastò, Riccardo Vida, Arianna Dri, et al.
The Breast (2024) Vol. 79, pp. 103859-103859
Closed Access | Times Cited: 1
CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials
Hangcheng Xu, Yan Wang, Yiqun Han, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 7

Scroll to top